Breaking News

CordenPharma Invests in Small Molecule API Development Capacity

Allows the CDMO to run an increasing number of early-phase projects

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CordenPharma said it is investing €3.7 million in the manufacturing site infrastructure of its CordenPharma Switzerland facility, located in Liestal, Switzerland. The investment will include an expansion of the square footage dedicated to small molecule, peptide and carbohydrate development services. In addition, an approximately €2 million investment in new automated development and optimization equipment is currently being realized to facilitate development services and an extensive upgrading ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters